Solid Organ Transplant Research

Current studies being conducted in the Solid Organ Transplant department at Children's:

  • Pharmacokinetics and Safety of Valganciclovir in Pediatric Heart Transplant Recipients Less Than 4 Months of Age 
    • The indication for this study is prevention of cytomegalovirus (CMV) disease in solid organ transplant recipients.  Transplant recipients are immunocompromised, and at greater risk for developing CMV.  Transplant recipients can acquire CMV infection from the organ donor or following multiple blood transfusions.  CMV can become latent and later reactivated in patients taking immunosuppressive drugs
    • Ganciclovir was the first antiviral drug approved for the treatment of human CMV infection and disease in certain populations.  The safety and efficacy of ganciclovir and valganciclovir, a pro-drug of ganciclovir, are well established in adults for the treatment and prevention of CMV disease.  In the absence of data in very young children, valganciclovir for the prevention of CMV disease is being studied in this age group
    • Patient must be a heart transplant recipient less than 4 months of age and be at risk of developing CMV disease. Patient must also be currently being treated with Iv ganciclovir or oral valganciclovir for prevention of CMV disease with adequate hematological and renal function and be able to tolerate oral medication
Principal Investigators:
  • Aliessa Barnes, MD 
For more information, contact:
  •  Deborah McElroy, RN, BSN (214) 456-8792